Universidad Peruana Cayetano Heredia

Drugs commonly associated with weight change: A systematic review and meta-analysis

Mostrar el registro sencillo del ítem

dc.contributor.author Domecq, J.P.
dc.contributor.author Prutsky, G.
dc.contributor.author Leppin, A.
dc.contributor.author Sonbol, M.B.
dc.contributor.author Altayar, O.
dc.contributor.author Undavalli, C.
dc.contributor.author Wang, Z.
dc.contributor.author Elraiyah, T.
dc.contributor.author Brito, J.P.
dc.contributor.author Mauck, K.F.
dc.contributor.author Lababidi, M.H.
dc.contributor.author Prokop, L.J.
dc.contributor.author Asi, N.
dc.contributor.author Wei, J.
dc.contributor.author Fidahussein, S.
dc.contributor.author Montori, V.M.
dc.contributor.author Murad, M.H.
dc.date.accessioned 2019-02-22T14:56:08Z
dc.date.available 2019-02-22T14:56:08Z
dc.date.issued 2015
dc.identifier.uri https://hdl.handle.net/20.500.12866/5835
dc.description.abstract Context: Various drugs affect body weight as a side effect. Objective: We conducted this systematic review and meta-analysis to summarize the evidence about commonly prescribed drugs and their association with weight change. Data Sources: MEDLINE, DARE, and the Cochrane Database of Systematic Reviews were searched to identify published systematic reviews as a source for trials. Study Selection: We included randomized trials that compared an a priori selected list of drugs to placebo and measured weight change. Data Extraction: We extracted data in duplicate and assessed the methodological quality using the Cochrane risk of bias tool. Results: We included 257 randomized trials (54 different drugs; 84 696 patients enrolled). Weight gain was associated with the use of amitriptyline (1.8 kg), mirtazapine (1.5 kg), olanzapine (2.4 kg), quetiapine (1.1 kg), risperidone (0.8 kg), gabapentin (2.2 kg), tolbutamide (2.8 kg), pioglitazone (2.6 kg), glimepiride (2.1 kg), gliclazide (1.8 kg), glyburide (2.6 kg), glipizide (2.2 kg), sitagliptin (0.55 kg), and nateglinide (0.3 kg). Weight loss was associated with the use of metformin (1.1 kg), acarbose (0.4 kg), miglitol (0.7 kg), pramlintide (2.3 kg), liraglutide (1.7 kg), exenatide (1.2 kg), zonisamide (7.7 kg), topiramate (3.8 kg), bupropion (1.3 kg), and fluoxetine (1.3 kg). For many other remaining drugs (including antihypertensives and antihistamines), the weight change was either statistically nonsignificant or supported by very low-quality evidence. Conclusions: Several drugs are associated with weight change of varying magnitude. Data are provided to guide the choice of drug when several options exist and institute preemptive weight loss strategies when obesogenic drugs are prescribed. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Journal of Clinical Endocrinology and Metabolism
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject human en_US
dc.subject Article en_US
dc.subject priority journal en_US
dc.subject adverse outcome en_US
dc.subject Hypoglycemic Agents en_US
dc.subject prescription en_US
dc.subject drug effect en_US
dc.subject weight reduction en_US
dc.subject Weight Loss en_US
dc.subject Body Weight en_US
dc.subject Weight Gain en_US
dc.subject body weight en_US
dc.subject meta analysis en_US
dc.subject drug effects en_US
dc.subject drug safety en_US
dc.subject drug tolerability en_US
dc.subject systematic review en_US
dc.subject drug choice en_US
dc.subject randomized controlled trial (topic) en_US
dc.subject antidiabetic agent en_US
dc.subject weight change en_US
dc.subject weight gain en_US
dc.subject metformin en_US
dc.subject pioglitazone en_US
dc.subject evidence based medicine en_US
dc.subject carbamazepine en_US
dc.subject glibenclamide en_US
dc.subject glimepiride en_US
dc.subject glipizide en_US
dc.subject sitagliptin en_US
dc.subject exendin 4 en_US
dc.subject liraglutide en_US
dc.subject acarbose en_US
dc.subject amfebutamone en_US
dc.subject amitriptyline en_US
dc.subject Antipsychotic Agents en_US
dc.subject aripiprazole en_US
dc.subject fluoxetine en_US
dc.subject gabapentin en_US
dc.subject gliclazide en_US
dc.subject medical decision making en_US
dc.subject miglitol en_US
dc.subject mirtazapine en_US
dc.subject nateglinide en_US
dc.subject neuroleptic agent en_US
dc.subject olanzapine en_US
dc.subject pramlintide en_US
dc.subject quetiapine en_US
dc.subject risperidone en_US
dc.subject topiramate en_US
dc.subject valproate semisodium en_US
dc.subject ziprasidone en_US
dc.subject zonisamide en_US
dc.title Drugs commonly associated with weight change: A systematic review and meta-analysis en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.1210/jc.2014-3421
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.18
dc.relation.issn 1945-7197


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas